Published in J Neurol on February 01, 2002
A review of structural magnetic resonance neuroimaging. J Neurol Neurosurg Psychiatry (2004) 1.06
Evidence for grey matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry (2004) 0.95
Abnormalities in normal appearing tissues in early primary progressive multiple sclerosis and their relation to disability: a tissue specific magnetisation transfer study. J Neurol Neurosurg Psychiatry (2006) 0.92
Deep gray matter and fatigue in MS: a T1 relaxation time study. J Neurol (2006) 0.92
Advanced MRI unravels the nature of tissue alterations in early multiple sclerosis. Ann Clin Transl Neurol (2014) 0.91
Increasing normal-appearing grey and white matter magnetisation transfer ratio abnormality in early relapsing-remitting multiple sclerosis. J Neurol (2005) 0.87
Quantification of magnetization transfer rate and native T1 relaxation time of the brain: correlation with magnetization transfer ratio measurements in patients with multiple sclerosis. Neuroradiology (2005) 0.85
Attention and memory dysfunctions in mild multiple sclerosis. Eur Arch Psychiatry Clin Neurosci (2005) 0.84
Microglial Fc receptors mediate physiological changes resulting from antibody cross-linking of myelin oligodendrocyte glycoprotein. J Neuroimmunol (2008) 0.82
Grey matter magnetization transfer ratio independently correlates with neurological deficit in secondary progressive multiple sclerosis. J Neurol (2009) 0.80
Examination of the role of magnetic resonance imaging in multiple sclerosis: A problem-orientated approach. Ann Indian Acad Neurol (2009) 0.80
Changes and variability of proton density and T1 relaxation times in early multiple sclerosis: MRI markers of neuronal damage in the cerebral cortex. Eur Radiol (2015) 0.79
Proteomic strategies in multiple sclerosis and its animal models. Proteomics Clin Appl (2007) 0.76
Statistical estimation of T1 relaxation times using conventional magnetic resonance imaging. Neuroimage (2015) 0.75
The Relationship between Gray Matter Quantitative MRI and Disability in Secondary Progressive Multiple Sclerosis. PLoS One (2016) 0.75
Comparison of two quantitative proton density mapping methods in multiple sclerosis. MAGMA (2016) 0.75
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med (2006) 11.29
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med (2012) 6.51
A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med (2002) 3.74
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet (2008) 3.68
MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol (2007) 3.47
Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol (2005) 3.45
Evidence for segregated and integrative connectivity patterns in the human Basal Ganglia. J Neurosci (2008) 3.43
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol (2009) 3.42
Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol (2004) 3.23
Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol (2012) 3.15
Functional-anatomical validation and individual variation of diffusion tractography-based segmentation of the human thalamus. Cereb Cortex (2004) 3.03
Normal cerebral perfusion measurements using arterial spin labeling: reproducibility, stability, and age and gender effects. Magn Reson Med (2004) 2.71
Orientationally invariant indices of axon diameter and density from diffusion MRI. Neuroimage (2010) 2.70
PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans. Nature (2007) 2.63
Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol (2007) 2.53
Hemispheric asymmetries in language-related pathways: a combined functional MRI and tractography study. Neuroimage (2006) 2.49
The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol (2005) 2.44
MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurol (2006) 2.44
Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol (2009) 2.43
Estimating distributed anatomical connectivity using fast marching methods and diffusion tensor imaging. IEEE Trans Med Imaging (2002) 2.38
Diffusion tensor imaging of post mortem multiple sclerosis brain. Neuroimage (2006) 2.35
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain (2002) 2.30
Neuroplasticity predicts outcome of optic neuritis independent of tissue damage. Ann Neurol (2010) 2.24
Amygdala hypoactivity to fearful faces in boys with conduct problems and callous-unemotional traits. Am J Psychiatry (2008) 2.21
An investigation of the retinal nerve fibre layer in progressive multiple sclerosis using optical coherence tomography. Brain (2007) 2.18
Initial demonstration of in vivo tracing of axonal projections in the macaque brain and comparison with the human brain using diffusion tensor imaging and fast marching tractography. Neuroimage (2002) 2.14
Diffusion tensor imaging in schizophrenia. Biol Psychiatry (2005) 2.14
MRI in multiple sclerosis: current status and future prospects. Lancet Neurol (2008) 2.08
Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res (2007) 2.08
Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med (2007) 2.06
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol (2010) 2.03
Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol (2012) 2.01
Quality of life measurement after stroke: uses and abuses of the SF-36. Stroke (2002) 2.00
Motor system activation after subcortical stroke depends on corticospinal system integrity. Brain (2006) 1.99
Adolescent impulsivity phenotypes characterized by distinct brain networks. Nat Neurosci (2012) 1.98
White matter integrity and cognitive impairment in first-episode psychosis. Am J Psychiatry (2010) 1.92
Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol (2008) 1.91
Study design in fMRI: basic principles. Brain Cogn (2006) 1.91
Optimal imaging parameters for fiber-orientation estimation in diffusion MRI. Neuroimage (2005) 1.90
Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol (2007) 1.88
Quantitative magnetic resonance of postmortem multiple sclerosis brain before and after fixation. Magn Reson Med (2008) 1.82
Tract-specific anisotropy measurements in diffusion tensor imaging. Psychiatry Res (2005) 1.79
Investigating cervical spinal cord structure using axial diffusion tensor imaging. Neuroimage (2002) 1.76
Identical, but not the same: intra-site and inter-site reproducibility of fractional anisotropy measures on two 3.0T scanners. Neuroimage (2010) 1.75
A diffusion tensor imaging study of fasciculi in schizophrenia. Am J Psychiatry (2007) 1.71
Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain (2004) 1.71
Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol (2012) 1.70
Effect sizes can be misleading: is it time to change the way we measure change? J Neurol Neurosurg Psychiatry (2010) 1.70
Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biol Psychiatry (2010) 1.69
Combined functional MRI and tractography to demonstrate the connectivity of the human primary motor cortex in vivo. Neuroimage (2003) 1.69
New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes. Ann Neurol (2003) 1.66
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain (2003) 1.62
The evolution of prefrontal inputs to the cortico-pontine system: diffusion imaging evidence from Macaque monkeys and humans. Cereb Cortex (2005) 1.61
Size matters: increased grey matter in boys with conduct problems and callous-unemotional traits. Brain (2009) 1.61
Clinically isolated syndromes. Lancet Neurol (2012) 1.59
Patient-based outcomes of cervical dystonia: a review of rating scales. Mov Disord (2004) 1.59
Disability, atrophy and cortical reorganization following spinal cord injury. Brain (2011) 1.58
Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol (2002) 1.57
Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives. Lancet Oncol (2008) 1.57
Risk taking and the adolescent reward system: a potential common link to substance abuse. Am J Psychiatry (2011) 1.56
Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res (2009) 1.56
Motor system hyperconnectivity in juvenile myoclonic epilepsy: a cognitive functional magnetic resonance imaging study. Brain (2011) 1.55
Quantitative magnetization transfer imaging in postmortem multiple sclerosis brain. J Magn Reson Imaging (2007) 1.54
Exploring rating scale responsiveness: does the total score reflect the sum of its parts? Neurology (2004) 1.54
Reducing the impact of white matter lesions on automated measures of brain gray and white matter volumes. J Magn Reson Imaging (2010) 1.54
Optic nerve diffusion tensor imaging in optic neuritis. Neuroimage (2005) 1.54
Thalamotemporal impairment in temporal lobe epilepsy: a combined MRI analysis of structure, integrity, and connectivity. Epilepsia (2014) 1.53
Characterizing function-structure relationships in the human visual system with functional MRI and diffusion tensor imaging. Neuroimage (2004) 1.52
The therapeutic potential of cannabis. Lancet Neurol (2003) 1.49
Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol Psychiatry (2009) 1.49
A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials. Brain (2010) 1.48
White matter connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington's disease. Brain (2007) 1.47
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol (2009) 1.46
Functional anatomy of interhemispheric cortical connections in the human brain. J Anat (2006) 1.45
Distortion correction for diffusion-weighted MRI tractography and fMRI in the temporal lobes. Hum Brain Mapp (2010) 1.43